Myriad Milestones

Our Beginning

Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history.


First Gene Discovery

Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma.


BRCA1 Discovery

Myriad scientists publish in Science the discovery of the BRCA1 gene that is associated with hereditary breast and ovarian cancer.


Public Company

Myriad becomes a public company and is traded on NASDAQ under the ticker: MYGN.


BRCA2 Discovery

Myriad announces the discovery of the BRCA2 gene that is associated with hereditary breast and ovarian cancer.


BRACAnalysis ® Launches

Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market.


DEP1 Discovery

Myriad announces the discovery of major depression gene DEP1 in collaboration with Abbott Laboratories.


Preventative BRACAnalysis ® Launches

Myriad launches BRACAnalysis® for the women’s health preventative care market, significantly expanding access to genetic cancer testing.


Prolaris® Launches

Myriad launched Prolaris®, the first ever prognostic test to predict prostate cancer survival.


PARP Companion Diagnostics

Myriad enters into three companion diagnostic collaborations for PARP inhibitors used in patients with ovarian cancer.


One-Million Milestone

The one-millionth patient is tested with BRACAnalysis® test.


myRisk® Launches

Myriad launches Myriad myRisk® Hereditary Cancer, a multi-gene panel test for eight hereditary cancers.


BRACAnalysis CDx® Receives FDA Approval

Myriad receives FDA approval for its BRACAnalysis CDx® test to identify ovarian cancer patients who may benefit from the PARP inhibitor Lynparza (olaparib).


Expansion into Mental Health

Myriad acquires Assurex Health and the GeneSight® genetic test for several mental health conditions.


EndoPredict® Launches

EndoPredict® test is launched in the United States, providing three separate results to optimize treatment for patients with breast cancer.


riskScore® Launches

Myriad launches riskScore® test, providing eligible women with a comprehensive, personalized breast cancer risk assessment.


BRACAnalysis CDx® Companion Diagnostic

Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for Lynparza in patients with metastatic breast cancer.


Expansion into Reproductive Health

Myriad acquires Counsyl and enters the reproductive genetic testing market.


riskScore® Validation in Additional Ancestries

Myriad validates first ever polygenic score to predict breast cancer risk in women of Hispanic ancestry


Paul Diaz Named CEO

Paul J. Diaz appointed President and Chief Executive Officer of Myriad Genetics.


Helping More Patients

Myriad Genetics joins forces with Intermountain Precision Genomics for a comprehensive offering of germline and somatic tumor testing services.


All Ancestries

Expanding access to genetic testing with launch of first polygenic breast cancer risk assessment score validated for women of all ancestries.


Advancing precision oncology with the launch of Precise™ Solutions.

New offering combines genetic insights from multiple tests to guide treatment decisions and improve patient care.